Fresenius appoints Mahl as Fresenius stock sits at EUR 45.96

Published on 10/25/2026 at 17:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius stock trades at EUR 45.96 in weekend trading on October 25, 2026 versus the Xetra close of EUR 46.10. The board change dates to October 15, 2026.

Leadership changes and next session

On October 15, 2026, Fresenius appointed Marc-Alexander Mahl to its Management Board.
Fresenius stock trades at EUR 45.96 at 5:42 p.m. CEST on October 25, 2026, 0.30 percent below the Xetra close of October 23, 2026.
The next Xetra session is scheduled for October 26, 2026.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius appointed Marc-Alexander Mahl to its Management Board on October 15, 2026, while extending Chief Financial Officer Sara Hennicken’s contract for another five years, according to an EQS announcement carried by the Financial Times. Mahl is due to succeed Pierluigi Antonelli and take responsibility for the Fresenius Kabi businesses effective November 1, 2026. Hennicken’s contract will run through 2032.

Market context: Market report DAX.

The week in figures

Xetra closed Fresenius at EUR 46.10 on October 23, 2026. At 5:42 p.m. CEST on October 25, 2026, the stock traded at EUR 45.96 in weekend trading at Lang & Schwarz, 0.30 percent below the Xetra close of October 23, 2026.

The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Fresenius stock.

Chronology of the week

On October 15, 2026, Fresenius announced the appointment of Mahl to its Management Board, the extension of Hennicken’s contract through 2032 and a new leadership structure for its Nutrition business. The announcement was distributed by EQS and is available through the Financial Times.